摘要
目的探讨低分子肝素治疗重度子痫前期的应用价值及可行性。方法 2008年3月至2009年12月在首都医科大学附属北京妇产医院住院分娩的重度子痫前期患者分为对照组30例,治疗1组30例,治疗2组20例。对照组给予硫酸镁静脉滴注,治疗1、2组在此基础上加用低分子肝素,分别连用5、10～13d。记录各组治疗前后相关指标的变化。结果治疗后,治疗1、2组平均动脉压和血细胞比容均比对照组下降,治疗1、2组每日尿量比对照组增加,且治疗2组每日尿量高于治疗1组,差异均有统计学意义(P<0.05)。治疗前后24h尿蛋白、血小板计数、D-二聚体及产后出血量组间比较,差异均无统计学意义(P>0.05)。结论低分子肝素可改善重度子痫前期患者的平均动脉压、每日尿量及血细胞比容,不影响血小板计数和产后出血量,临床可推广使用。
Objective To evaluate the practical value and feasibility of low-molecular-weight heparin（LMWH） in the treatment of severe pre-eclampsia.Methods The patients with severe pre-eclampsia delivering in Beijing Hospital of Obstetrics and Gynecology,Capital Medical University from March 2008 to December 2009 were randomly divided into control group（n = 30）,treatment group 1（n = 30） and treatment group 2（n = 20）.The patients in control group were given magnesium sulfate by intravenous infusion,whereas treatment group 1 or 2 received addtional daily subcutaneous injection of LMWH for 5 or 10 days.The data of mean arterial pressure（MAP）,urine volume per day,24-hour urine protein,hematocrit,platelet count,D-dimer and postpartum bleeding in each group were recorded before and after treatment.Results The MAP in treatment group 1 and 2 decreased compared with those in control group;the urine volume per day in treatment group 1 and 2 increased compared with those in control group;the urine volume per day in treatment group 2 increased compared with those in treatment group 1;the HCT in treatment group 1 and 2 decreased compared with those in control group（P 0.05）.The comparison of 24-hour urine protein,platelet count,D-dimer and postpartum bleeding before and after treatment in each group did not show statistically significant difference（P 0.05）.Conclusion LMWH could improve MAP,urine volume per day and HCT in patients with severe pre-eclampsia and did not affect the platelet count and postpartum bleeding.It could be used widely.
出处
《医学综述》
2010年第16期2515-2517,共3页
Medical Recapitulate
关键词
低分子肝素
重度子痫前期
应用价值
Low molecular weight heparin
Severe pre-eclampsia
Practical value
